ArticleProstate cancer and prostatic diseases2025
Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer.
Article in Prostate cancer and prostatic diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- From reflex to reason: rethinking pelvic lymph node dissection in the PSMA PET Era.European journal of nuclear medicine and molecular imaging · 2026Article
- Diagnostic and prognostic utility of PSMA-PET/CT in node-metastatic prostate cancer.BJU international · 2026Article
- Surgical Management of PSMA PET-Positive Lymph Nodes in Prostate Cancer.Current urology reports · 2026Review
- Low-PSMA hormone-sensitive prostate cancer: a distinct clinical and molecular state.Molecular medicine (Cambridge, Mass.) · 2026Article
- PSMA PET in Lymph Node Staging of Prostate Cancer: From Diagnostic Accuracy to Clinical Decision-Making.Cancers · 2026Review
- Changing Face of Radical Prostatectomy: A Nationwide Registry Study of Case-Mix, Surgical Evolution, and Outcomes.Cancers · 2026Article
- A novel nomogram incorporating lymphovascular invasion to predict lymph node invasion in high-risk prostate cancer.Scientific reports · 2026Article
- Diagnostic accuracy and outcomes of lymph node staging in intermediate-risk prostate cancer.BJU international · 2026Article
- The utility of pelvic lymph node dissection in PSMA-PET negative intermediate and high-risk prostate cancer patients undergoing radical prostatectomy.World journal of urology · 2026Article
- Oncolytic virus OH2 induces PD-L1 upregulation via NF-κB signaling and synergizes with anti-PD-L1 therapy in prostate cancer through a targeted extracellular vesicle delivery system.Journal for immunotherapy of cancer · 2026Article
- Impact of Negative Prostate-specific Membrane Antigen Positron Emission Tomography on the Decision to Perform a Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- to High-risk Prostate Cancer Patients: Results of an International Survey.European urology open science · 2026Article
- Observational
- Association of [Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate-specific membrane antigen (PSMA) positron emission tomography (PET) has a high negative predictive value (NPV) in determining lymph node invasion (LNI) in men with intermediate-risk disease undergoing radical prostatectomy (RP) and pelvic lymph node dissection (PLND). We hypothesized that PSMA PET may be used to reduce the number of unnecessary PLND procedures performed.
objectiveTo assess BCR-free survival of intermediate risk prostate cancer patients with a negative PSMA PET who underwent PLND vs. no PLND. DESIGN, SETTING, AND
participantsWithin a high-volume center database, we identified patients with Grade Group 2-3 and PSA ≤ 20 ng/ml who had a negative PSMA PET prior to RP between 2016 and 2021. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Kaplan-Meier analyses were used to compare BCR-free survival between patients with and without PLND. RESULTS AND LIMITATIONS: Overall, 371 patients were identified. Of those, 333 (90%) underwent RP with PLND, while 38 (10%) had no PLND during RP. Median number of removed lymph nodes in patients with PLND was 16. The NPV of PSMA PET for LNI detection was 90.1%. Median follow-up was 36 months. The median preoperative PSA was 7.8 ng/ml. 59% had biopsy Grade Group 2 and 41% had biopsy Grade Group 3, respectively. BCR-free survival at 36 months after prostatectomy was 78.7% vs. 76.7% (p = 0.8) for patients with vs. without PLND. Main limitation is the absence of long-term oncologic outcomes.
conclusionsIn intermediate risk prostate cancer patients, a PLND may be avoided in the presence of a negative PSMA PET.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.